Does the media prefer AXSM or SUPN?

In the previous week, Axsome Therapeutics had 1 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 6 mentions for Axsome Therapeutics and 5 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.52 beat Axsome Therapeutics' score of 0.14 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Axsome Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Supernus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media refer more to LNTH or SUPN?

In the previous week, Lantheus had 3 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 8 mentions for Lantheus and 5 mentions for Supernus Pharmaceuticals. Lantheus' average media sentiment score of 0.54 beat Supernus Pharmaceuticals' score of 0.52 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Supernus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Does the media prefer BLTE or SUPN?

In the previous week, Belite Bio had 1 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 6 mentions for Belite Bio and 5 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.52 beat Belite Bio's score of 0.48 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Belite Bio 0 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Supernus Pharmaceuticals 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive

Supernus Pharmaceuticals (SUPN) Competitors

$39.57 -0.61 (-1.52%)

As of 10/15/2026 04:00 PM Eastern

Compare

SUPN vs. AXSM, CRNX, AMRX, LNTH, and BLTE

Should you buy Supernus Pharmaceuticals stock or one of its competitors? Supernus Pharmaceuticals's main competitors and comparable companies include Axsome Therapeutics (AXSM), Crinetics Pharmaceuticals (CRNX), Amneal Pharmaceuticals (AMRX), Lantheus (LNTH), and Belite Bio (BLTE). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "pharmaceuticals" industry.

How does Supernus Pharmaceuticals compare to Axsome Therapeutics?

Axsome Therapeutics (NASDAQ:AXSM) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, media sentiment, earnings, profitability, valuation, analyst recommendations, institutional ownership and risk.

Axsome Therapeutics has a beta of 0.86, suggesting that its stock price is 14% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.55, suggesting that its stock price is 45% less volatile than the broader market.

Supernus Pharmaceuticals has a net margin of -13.23% compared to Axsome Therapeutics' net margin of -24.68%. Supernus Pharmaceuticals' return on equity of 11.13% beat Axsome Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Axsome Therapeutics	-24.68%	-265.55%	-28.10%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

81.5% of Axsome Therapeutics shares are owned by institutional investors. 20.6% of Axsome Therapeutics shares are owned by company insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Supernus Pharmaceuticals has higher revenue and earnings than Axsome Therapeutics. Axsome Therapeutics is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Axsome Therapeutics	$638.50M	13.27	-$183.17M	-$3.75	N/A
Supernus Pharmaceuticals	$718.95M	3.20	-$38.55M	-$1.92	N/A

Axsome Therapeutics presently has a consensus target price of $275.74, indicating a potential upside of 70.43%. Supernus Pharmaceuticals has a consensus target price of $62.40, indicating a potential upside of 57.70%. Given Axsome Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Axsome Therapeutics is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Axsome Therapeutics	1 Sell rating(s)	2 Hold rating(s)	17 Buy rating(s)	1 Strong Buy rating(s)	2.86
Supernus Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

In the previous week, Axsome Therapeutics had 1 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 6 mentions for Axsome Therapeutics and 5 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.52 beat Axsome Therapeutics' score of 0.14 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Axsome Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Supernus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Axsome Therapeutics beats Supernus Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Crinetics Pharmaceuticals (NASDAQ:CRNX) are both mid-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, risk, earnings, institutional ownership, media sentiment, profitability, dividends and analyst recommendations.

Supernus Pharmaceuticals has a net margin of -13.23% compared to Crinetics Pharmaceuticals' net margin of -1,189.88%. Supernus Pharmaceuticals' return on equity of 11.13% beat Crinetics Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Crinetics Pharmaceuticals	-1,189.88%	-44.22%	-39.77%

98.5% of Crinetics Pharmaceuticals shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 3.8% of Crinetics Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Supernus Pharmaceuticals has higher revenue and earnings than Crinetics Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Crinetics Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.20	-$38.55M	-$1.92	N/A
Crinetics Pharmaceuticals	$7.70M	1,170.54	-$465.32M	-$5.04	N/A

Supernus Pharmaceuticals has a beta of 0.55, meaning that its share price is 45% less volatile than the broader market. Comparatively, Crinetics Pharmaceuticals has a beta of 0.08, meaning that its share price is 92% less volatile than the broader market.

In the previous week, Supernus Pharmaceuticals had 5 more articles in the media than Crinetics Pharmaceuticals. MarketBeat recorded 5 mentions for Supernus Pharmaceuticals and 0 mentions for Crinetics Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.52 beat Crinetics Pharmaceuticals' score of 0.00 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Supernus Pharmaceuticals	Positive
Crinetics Pharmaceuticals	Neutral

Supernus Pharmaceuticals presently has a consensus price target of $62.40, indicating a potential upside of 57.70%. Crinetics Pharmaceuticals has a consensus price target of $83.44, indicating a potential downside of 1.77%. Given Supernus Pharmaceuticals' stronger consensus rating and higher possible upside, equities research analysts plainly believe Supernus Pharmaceuticals is more favorable than Crinetics Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Crinetics Pharmaceuticals	1 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.13

Summary

Supernus Pharmaceuticals beats Crinetics Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Amneal Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Amneal Pharmaceuticals (NASDAQ:AMRX) are both mid-cap healthcare companies, but which is the better business? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, dividends, media sentiment, risk, valuation and profitability.

Supernus Pharmaceuticals currently has a consensus target price of $62.40, suggesting a potential upside of 57.70%. Amneal Pharmaceuticals has a consensus target price of $21.00, suggesting a potential upside of 9.09%. Given Supernus Pharmaceuticals' higher probable upside, equities analysts plainly believe Supernus Pharmaceuticals is more favorable than Amneal Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17
Amneal Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.80

Amneal Pharmaceuticals has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Amneal Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$718.95M	3.20	-$38.55M	-$1.92	N/A
Amneal Pharmaceuticals	$3.02B	2.04	$72.06M	$0.49	39.29

In the previous week, Supernus Pharmaceuticals had 4 more articles in the media than Amneal Pharmaceuticals. MarketBeat recorded 5 mentions for Supernus Pharmaceuticals and 1 mentions for Amneal Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.52 beat Amneal Pharmaceuticals' score of 0.16 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Supernus Pharmaceuticals	Positive
Amneal Pharmaceuticals	Neutral

31.8% of Amneal Pharmaceuticals shares are owned by institutional investors. 8.5% of Supernus Pharmaceuticals shares are owned by company insiders. Comparatively, 17.3% of Amneal Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Amneal Pharmaceuticals has a net margin of 5.05% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Amneal Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%
Amneal Pharmaceuticals	5.05%	-584.46%	7.78%

Supernus Pharmaceuticals has a beta of 0.55, suggesting that its share price is 45% less volatile than the broader market. Comparatively, Amneal Pharmaceuticals has a beta of 1.22, suggesting that its share price is 22% more volatile than the broader market.

Summary

Amneal Pharmaceuticals beats Supernus Pharmaceuticals on 10 of the 16 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, dividends, risk, earnings, analyst recommendations, valuation, media sentiment and institutional ownership.

In the previous week, Lantheus had 3 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 8 mentions for Lantheus and 5 mentions for Supernus Pharmaceuticals. Lantheus' average media sentiment score of 0.54 beat Supernus Pharmaceuticals' score of 0.52 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Supernus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

99.1% of Lantheus shares are held by institutional investors. 1.7% of Lantheus shares are held by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Lantheus currently has a consensus target price of $107.44, indicating a potential upside of 7.46%. Supernus Pharmaceuticals has a consensus target price of $62.40, indicating a potential upside of 57.70%. Given Supernus Pharmaceuticals' higher possible upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	11 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.21
Supernus Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

Lantheus has a net margin of 17.69% compared to Supernus Pharmaceuticals' net margin of -13.23%. Lantheus' return on equity of 28.10% beat Supernus Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	17.69%	28.10%	14.35%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Lantheus has a beta of -0.06, meaning that its stock price is 106% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

Lantheus has higher revenue and earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.54B	4.23	$233.56M	$4.14	24.15
Supernus Pharmaceuticals	$718.95M	3.20	-$38.55M	-$1.92	N/A

Summary

Lantheus beats Supernus Pharmaceuticals on 12 of the 15 factors compared between the two stocks.

How does Supernus Pharmaceuticals compare to Belite Bio?

Belite Bio (NASDAQ:BLTE) and Supernus Pharmaceuticals (NASDAQ:SUPN) are both mid-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their dividends, risk, analyst recommendations, media sentiment, profitability, institutional ownership, earnings and valuation.

Belite Bio has a net margin of 0.00% compared to Supernus Pharmaceuticals' net margin of -13.23%. Supernus Pharmaceuticals' return on equity of 11.13% beat Belite Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Belite Bio	N/A	-11.84%	-11.62%
Supernus Pharmaceuticals	-13.23%	11.13%	8.10%

Supernus Pharmaceuticals has higher revenue and earnings than Belite Bio. Belite Bio is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Belite Bio	N/A	N/A	-$77.61M	-$2.73	N/A
Supernus Pharmaceuticals	$718.95M	3.20	-$38.55M	-$1.92	N/A

Belite Bio has a beta of -1.23, meaning that its stock price is 223% less volatile than the broader market. Comparatively, Supernus Pharmaceuticals has a beta of 0.55, meaning that its stock price is 45% less volatile than the broader market.

Belite Bio currently has a consensus price target of $218.73, indicating a potential upside of 43.31%. Supernus Pharmaceuticals has a consensus price target of $62.40, indicating a potential upside of 57.70%. Given Supernus Pharmaceuticals' higher probable upside, analysts plainly believe Supernus Pharmaceuticals is more favorable than Belite Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Belite Bio	1 Sell rating(s)	2 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.64
Supernus Pharmaceuticals	2 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.17

0.5% of Belite Bio shares are owned by institutional investors. 13.3% of Belite Bio shares are owned by insiders. Comparatively, 8.5% of Supernus Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

In the previous week, Belite Bio had 1 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 6 mentions for Belite Bio and 5 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.52 beat Belite Bio's score of 0.48 indicating that Supernus Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Belite Bio	0 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Supernus Pharmaceuticals	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Summary

Supernus Pharmaceuticals beats Belite Bio on 9 of the 15 factors compared between the two stocks.

Get Supernus Pharmaceuticals News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SUPN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SUPN vs. The Competition

Export

Metric	Supernus Pharmaceuticals	Pharmaceuticals Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.34B	$12.46B	$7.31B	$12.93B
Dividend Yield	N/A	2.62%	2.51%	19.61%
P/E Ratio	-20.61	637.75	205.41	19.57
Price / Sales	3.20	749.93	572.85	87.12
Price / Cash	10.64	83.43	76.19	51.56
Price / Book	2.14	9.32	10.32	6.01
Net Income	-$38.55M	$2.84B	$3.50B	$380.68M
7 Day Performance	-7.27%	-3.81%	-3.34%	-3.15%
1 Month Performance	-4.37%	-6.99%	-6.60%	-5.18%
1 Year Performance	-20.48%	-4.61%	2.69%	-4.07%

Supernus Pharmaceuticals Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SUPN Supernus Pharmaceuticals	3.622 of 5 stars	$39.57 -1.5%	$62.40 +57.7%	-19.7%	$2.34B	$718.95M	N/A	778	News Coverage
AXSM Axsome Therapeutics	3.1742 of 5 stars	$175.08 -1.1%	$275.84 +57.6%	+24.9%	$9.21B	$776.57M	N/A	925	Analyst Forecast
CRNX Crinetics Pharmaceuticals	0.2114 of 5 stars	$84.95 flat	$83.44 -1.8%	N/A	$9.01B	$7.70M	N/A	210
AMRX Amneal Pharmaceuticals	3.8613 of 5 stars	$20.41 +0.3%	$21.00 +2.9%	+96.8%	$6.53B	$3.12B	41.72	8,500
LNTH Lantheus	3.6637 of 5 stars	$99.98 -0.2%	$108.11 +8.1%	+76.9%	$6.53B	$1.54B	24.16	1,193	Analyst Forecast

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SUPN) was last updated on 10/16/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Supernus Pharmaceuticals (SUPN) Competitors

SUPN vs. AXSM, CRNX, AMRX, LNTH, and BLTE

How does Supernus Pharmaceuticals compare to Axsome Therapeutics?

Summary

How does Supernus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Summary

How does Supernus Pharmaceuticals compare to Amneal Pharmaceuticals?

Summary

How does Supernus Pharmaceuticals compare to Lantheus?

Summary

How does Supernus Pharmaceuticals compare to Belite Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN vs. The Competition

Supernus Pharmaceuticals Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Supernus Pharmaceuticals (SUPN) Competitors

SUPN vs. AXSM, CRNX, AMRX, LNTH, and BLTE

How does Supernus Pharmaceuticals compare to Axsome Therapeutics?

Which has more volatility & risk, AXSM or SUPN?

Is AXSM or SUPN more profitable?

Do institutionals and insiders believe in AXSM or SUPN?

Which has better valuation and earnings, AXSM or SUPN?

Do analysts recommend AXSM or SUPN?

Does the media prefer AXSM or SUPN?

Summary

How does Supernus Pharmaceuticals compare to Crinetics Pharmaceuticals?

Is SUPN or CRNX more profitable?

Do insiders and institutionals have more ownership in SUPN or CRNX?

Which has stronger valuation & earnings, SUPN or CRNX?

Which has more risk and volatility, SUPN or CRNX?

Does the media refer more to SUPN or CRNX?

Do analysts recommend SUPN or CRNX?

Summary

How does Supernus Pharmaceuticals compare to Amneal Pharmaceuticals?

Do analysts recommend SUPN or AMRX?

Which has higher valuation and earnings, SUPN or AMRX?

Does the media favor SUPN or AMRX?

Do institutionals & insiders have more ownership in SUPN or AMRX?

Is SUPN or AMRX more profitable?

Which has more volatility and risk, SUPN or AMRX?

Summary

How does Supernus Pharmaceuticals compare to Lantheus?

Does the media refer more to LNTH or SUPN?

Do insiders & institutionals hold more shares of LNTH or SUPN?

Do analysts recommend LNTH or SUPN?

Is LNTH or SUPN more profitable?

Which has more risk & volatility, LNTH or SUPN?

Which has better valuation & earnings, LNTH or SUPN?

Summary

How does Supernus Pharmaceuticals compare to Belite Bio?

Is BLTE or SUPN more profitable?

Which has preferable earnings & valuation, BLTE or SUPN?

Which has more volatility and risk, BLTE or SUPN?

Do analysts rate BLTE or SUPN?

Do insiders and institutionals believe in BLTE or SUPN?

Does the media prefer BLTE or SUPN?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SUPN vs. The Competition

Supernus Pharmaceuticals Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools